Literature DB >> 8792118

Neurobiology of treatment-resistant schizophrenia: new insights and new models.

L J Beerpoot1, B K Lipska, D R Weinberger.   

Abstract

In an attempt to understand schizophrenia, four important fields have been implicated in the disease process and are reviewed here. Early findings that antipsychotic drugs were dopamine antagonists led to a dopaminergic theory of schizophrenia. However, it now appears that a primary dopaminergic abnormality is an unlikely explanation. The cortex has always been thought to be involved in the development of schizophrenia and recent data from neuropsychological, postmortem and imaging studies have indicated that connections between the prefrontal and temporolimbic areas within the brain may be abnormal. Traditionally, schizophrenia has been considered to be a disease with an adult onset pathology. This theory has now been challenged by data suggesting that in schizophrenia, anatomical changes in the adult brain are non-progressive and occurred prior to the onset of illness. Finally, studies on neuronal gene expression have indicated that all antipsychotic drugs modulate DNA transcription in the shell of the nucleus accumbens and that newer antipsychotics produce a quite different pattern of expression from conventional neuroleptics. These recent approaches provide new opportunities in the understanding of schizophrenia, its treatment and prevention.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8792118     DOI: 10.1016/0924-977x(96)00008-9

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  6 in total

Review 1.  Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy.

Authors:  Amy R Brooks-Kayal; Kevin G Bath; Anne T Berg; Aristea S Galanopoulou; Gregory L Holmes; Frances E Jensen; Andres M Kanner; Terence J O'Brien; Vicky H Whittemore; Melodie R Winawer; Manisha Patel; Helen E Scharfman
Journal:  Epilepsia       Date:  2013-08       Impact factor: 5.864

2.  ΔFosB induction in prefrontal cortex by antipsychotic drugs is associated with negative behavioral outcomes.

Authors:  David M Dietz; Pamela J Kennedy; Haosheng Sun; Ian Maze; Amy M Gancarz; Vincent Vialou; Ja Wook Koo; Ezekiell Mouzon; Subroto Ghose; Carol A Tamminga; Eric J Nestler
Journal:  Neuropsychopharmacology       Date:  2013-09-26       Impact factor: 7.853

3.  Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.

Authors:  Shahza M Somerville; Adrienne C Lahti; Robert R Conley; Rosalinda C Roberts
Journal:  Synapse       Date:  2011-03       Impact factor: 2.562

Review 4.  Postmortem brain: an underutilized substrate for studying severe mental illness.

Authors:  Robert E McCullumsmith; John H Hammond; Dan Shan; James H Meador-Woodruff
Journal:  Neuropsychopharmacology       Date:  2013-10-04       Impact factor: 7.853

Review 5.  Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.

Authors:  Emma Perez-Costas; Miguel Melendez-Ferro; Rosalinda C Roberts
Journal:  J Neurochem       Date:  2010-01-20       Impact factor: 5.372

6.  Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response.

Authors:  Rosalinda C Roberts; Joy K Roche; Robert R Conley; Adrienne C Lahti
Journal:  Synapse       Date:  2009-06       Impact factor: 2.562

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.